TipRanks
Go Ultimate55% OFF

Cann Group (CAN) AI Stock Analysis

AU:CAN

Cann Group

(ASX:CAN)

Select Model
Rating:37Underperform
Price Target:AUD 0.01â–¼(-10.00% Downside)
Action:downgraded
Date:09/06/26

The overall score is at the absolute minimum, reflecting a company in severe financial distress. The most significant factor is the fundamental disconnect between reported earnings and cash generation, with a collapsing gross margin and persistent operating cash burn indicating a non-viable core business. The recovery on the balance sheet is superficial, driven by asset shrinkage. The extremely low stock price and lack of technical or valuation support reinforce the critical risk profile.

Positive Factors
Improved Balance SheetThe latest balance sheet is materially more manageable than the prior year, when equity was negative and leverage was distorted. A debt-to-equity ratio of about 0.59 provides a stronger capital base and may improve the company’s ability to sustain operations and pursue recovery.
Negative Factors
Declining RevenueA sharp revenue decline indicates weakening commercial traction in the company’s medicinal cannabis operations and reduces the scale available to absorb fixed costs. Unless reversed, sustained contraction can limit operating leverage, make profitability harder to achieve, and increase dependence on financing or restructuring actions.

Cann Group (CAN) vs. iShares MSCI Australia ETF (EWA)

-10%-5%0%5%10%15%20%AU:CAN-9.09%EWA+13.51%Dec '25Jan '26
Market Cap
AUD 4.92M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
0.3
Beta (1Y)
0.61
Revenue Growth
-24.22%
EPS Growth
―
Country
Australia
Employees
40
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Cann Group Business Overview & Revenue Model

Company Description

Cann Group Limited, established in Port Melbourne, Australia, in 2014, specializes in the comprehensive lifecycle of medicinal cannabis. This includes genetic development, cultivation, manufacturing, clinical assessment, and the distribution of thera...

How the Company Makes Money

Cann Group makes money primarily by selling medicinal cannabis products and/or cannabis-derived inputs (such as dried flower and extracts) produced from its cultivation and manufacturing operations. Revenue is generated through supply arrangements wi...

Cann Group Financial Statement Overview

Summary

Financial health is critically weak. The TTM gross margin has collapsed to -94.1%, revenue is contracting at -24.3%, and the core business consistently burns cash with negative operating cash flow. A large TTM net profit is an anomaly contradicted by operational losses, indicating poor earnings quality. The balance sheet has recovered from insolvency but through asset shrinkage, not growth.

Income Statement

18Very Negative

Balance Sheet

35Negative

Cash Flow

10Very Negative
Financial statement breakdown
BreakdownTTMJun 2026Jun 2025Jun 2024Jun 2023Jun 2022
Income Statement
Total Revenue8.56M8.56M13.25M15.37M13.78M6.41M
Gross Profit-8.06M-8.06M5.15M-21.75M20.63M11.24M
EBITDA-5.42M-6.16M-8.94M-35.54M-24.63M-24.36M
Net Income20.30M20.30M-22.34M-51.24M-33.79M-26.47M
Balance Sheet
Total Assets51.99M51.99M78.79M92.77M129.47M139.66M
Cash, Cash Equivalents and Short-Term Investments490.00K490.00K10.00K1.64M765.00K1.91M
Total Debt16.84M16.84M75.84M72.47M60.97M47.16M
Total Liabilities23.39M23.39M81.56M78.85M70.20M54.76M
Stockholders Equity28.61M28.61M-2.77M13.92M59.26M84.90M
Cash Flow
Free Cash Flow-1.74M-1.74M-9.80M-17.69M-25.94M-65.60M
Operating Cash Flow-1.33M-1.33M-9.64M-15.19M-22.84M-20.43M
Investing Cash Flow-406.00K-406.00K-157.00K1.18M-28.00K-45.16M
Financing Cash Flow2.22M2.22M8.17M14.77M21.71M64.41M

Cann Group Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:CAN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:LGPAU:LGP45NeutralAUD 49.68M-13.04-1.67%―15.21%-141.82%
AU:VITAU:VIT44NeutralAUD 13.25M-2.98-9.80%―5.74%-222.22%
AU:EXLAU:EXL43NeutralAUD 2.72M-0.59-50.35%―-4.87%-9.78%
AU:IDTAU:IDT41NeutralAUD 18.20M-6.88-13.81%―5.93%66.32%
AU:PKPAU:PKP39UnderperformAUD 21.43M-5.074388.00%―-19.73%50.34%
AU:CANAU:CAN37UnderperformAUD 8.30M0.3064.70%―-24.22%―

* Healthcare Sector Average

Performance Comparison

-75%-50%-25%0%25%AU:CANAU:EXLAU:LGPAU:PKPAU:IDTAU:VITDec '25Jan '26
AU:CAN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:CANCann Group Ltd.0.01-0.00-9.09%
AU:EXLElixinol Wellness Ltd0.010.0025.00%
AU:LGPLittle Green Pharma Ltd.0.06-0.07-53.85%
AU:PKPAlthea Group Holdings Ltd.0.02-0.01-23.81%
AU:IDTIDT Australia Limited0.04-0.02-26.67%
AU:VITCronos Australia Ltd.0.02-0.04-67.74%

Cann Group Corporate Events

Cann Group Swings to Profit as Debt Deal and Export Push Reset Its Balance Sheet

Aug 31, 2026

Cann Group has executed a major balance sheet and cost reset, turning a prior-year net deficiency into net assets of $29.1 million and reporting a statutory net profit after tax of $20.3 million. The restructuring included settling $70.6 million of b...

Cann Group appoints Stannards Audit as new company auditor

Jul 13, 2026

Cann Group Limited, an Australian medicinal cannabis producer, manufactures and researches cannabis medicines at a large-scale GMP facility near Mildura, Victoria. Through its Botanitech and Mallee Bloom brands, along with bulk and white-label channe...

Cann Group Redeems Convertible Notes, Streamlining Capital Structure

Jul 6, 2026

Cann Group Limited operates in the medicinal cannabis sector, focusing on the cultivation and production of cannabis-based products for regulated markets. The company is listed on the ASX under the ticker CAN and manages various forms of capital, inc...

Cann Group Secures $2m Increase to Private Credit Loan Facility

Jul 3, 2026

Cann Group Limited has agreed with its private credit lender to increase the total commitment under its existing loan facility by $2 million, less establishment fees, on the same terms as the current arrangement. The additional funding can only be dr...

Regal Partners exits substantial holding in Cann Group

Jun 29, 2026

Regal Partners Funds Management Pty Ltd and its associates have filed a notice stating they have ceased to be substantial holders in Cann Group Ltd. The change follows a series of share disposals in June 2026, culminating in the sale of more than 36...

Cann Group Seeks ASX Quotation for 19.2 Million New Shares

Jun 18, 2026

Cann Group Limited has applied for quotation on the ASX of 19,189,759 ordinary fully paid shares, with an issue date of 18 June 2026. The new securities arise from the exercise or conversion of existing options or other convertible instruments, expan...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 06, 2026